About 30 results found for searched term "Glucagon Receptor" (0.096 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1601 | Dulaglutide (Activated main chain) | GLP Receptor |
| Dulaglutide (Activated main chain) is a glucagon-like peptide-1 receptor agonist (GLP-1 agonist) consisting of GLP-1(7-37) covalently linked to an Fc fragment of human IgG4. | ||
| M4344 | Shanzhiside-methylester | GLP Receptor |
| Shanzhiside Methyl ester was isolated from Lactobacillus rotaformis. Shanzhiside Methyl ester, a small molecule glucagon-like peptide 1 (GLP-1 receptor) agonist, has the ability to induce anti-abnormal pain tolerance. | ||
| M6878 | L-168,049 | Others |
| L-168,049 is a potent, orally active human glucagon receptor antagonist. | ||
| M9487 | Tirzepatide hydrochloride | GLP Receptor |
| LY3298176 hydrochloride | ||
| Tirzepatide Hydrochloride is a first-in-class glucose-dependent insulin-stimulating peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist for the study of diabetes mellitus. | ||
| M8101 | PF-06412154 hydrochloride | Others |
| PF-06412154 hydrochloride is a glucagon receptor antagonist. | ||
| M8113 | PF-06291874 | Glucagon Receptor |
| PF-06291874 is an orally active, potent and selective glucagon receptor antagonist. | ||
| M8394 | BETP | GLP Receptor |
| BETP is an agonist of glucagon-like peptide-1 (GLP-1) receptor, with EC50s of 0.66 and 0.755 μM for human and rat GLP-1 receptor, respectively. | ||
| M8940 | GRA Ex-25 | Glucagon Receptor |
| GRA Ex-25 is an inhibitor of glucagon receptor, with IC50 values of 56 and 55 nM for rat and human glucagon receptors, respectively. | ||
| M9190 | Lixisenatide | GLP Receptor |
| Lyxumia; Adlyxin; ZP10A peptide | ||
| Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is a hormone that helps normalize blood sugar levels. | ||
| M9749 | Cotadutide acetate | GLP Receptor |
| MEDI0382 acetate | ||
| Cotadutide acetate is a potent peptide dual agonist of glucagon-like peptide-1 (GLP-1) and glucagon receptor, with EC50 values of 6.9 pM and 10.2 pM, respectively. | ||
| M10034 | Exendin-4 | GLP Receptor |
| Exenatide | ||
| Exenatide (AC2993) is a first-in-class glucagon-like peptide 1 (GLP-1) receptor agonist consisting of 39 amino acids. | ||
| M10144 | NNC0640 | Glucagon Receptor |
| NNC-0640 | ||
| NNC0640 is a potent, negative allosteric modulator (NAM) of human G-protein-coupled glucagon receptor (GCGR) with IC50 of 69.2 nM. | ||
| M10311 | Danuglipron (PF-06882961) | GLP Receptor |
| PF06882961; Danuglipron | ||
| Danuglipron (PF-06882961) is a potent, orally bioavailable agonist of the glucagon-like peptide-1 receptor (GLP-1R) agonist. | ||
| M10802 | Exenatide Acetate (Exendin-4) | GLP Receptor |
| Exenatide Acetate (Exendin-4) is a first-in-class glucagon-like peptide 1 (GLP-1) receptor agonist consisting of 39 amino acids. | ||
| M10914 | Dasiglucagon acetate | Glucagon Receptor |
| Dasiglucagon (Zegalogue) acetate is a Glucagon Receptor Agonist. The physiologic effect of dasiglucagon is by means of Increased Glycogenolysis. | ||
| M21288 | LY3502970 | GLP Receptor |
| GLP-1 receptor agonist 1; Orforglipron | ||
| LY3502970 (GLP-1 receptor agonist 1) is an orally active glucagon-like peptide (GLP-1) receptor partial agonist for studies related to type 2 diabetes and obesity. | ||
| M11428 | LSN3318839 | GLP Receptor |
| LSN3318839 is an orally active allosteric modulator of glucagon-like peptide-1 receptor (GLP-1R). | ||
| M13966 | Adomeglivant | Glucagon Receptor |
| LY2409021 | ||
| Adomeglivant (LY2409021) is a potent, selective glucagon receptor (GluR) allosteric antagonist. Adomeglivant is widely used in the research for type 2 diabetes mellitus. | ||
| M13970 | Lixisenatide acetate | GLP Receptor |
| Lixisenatide acetate is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM). | ||
| M13971 | MK 0893 | Glucagon Receptor |
| MK 0893 is a potent and selective glucagon receptor antagonist with an IC50 of 6.6 nM. | ||
| M13972 | Semaglutide TFA | GLP Receptor |
| Semaglutide TFA, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide TFA has the potential for type 2 diabetes treatment. | ||
| M21371 | Tirzepatide | GLP Receptor |
| LY3298176 | ||
| Tirzepatide (LY3298176) is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist with potential use in type 2 diabetes research. | ||
| M21377 | PF-06372222 | Others |
| PF-06372222 is a small-molecule negative allosteric modulator of the glucagon receptor (GCGR). PF-06372222 is also an antagonist for glucagon-like peptide-1 receptor GLP-1R, which inhibits glucagon secretion and glucose-dependent insulin secretion. | ||
| M21658 | Taspoglutide | GLP Receptor |
| ITM077; R1583; BIM51077 | ||
| Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist developed for treatment of type 2 diabetes, with an EC50 value of 0.06 nM. | ||
| M24584 | Volagidemab | Others |
| REMD-477; AMG-477 | ||
| Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D). | ||
| M24689 | Crotedumab | Others |
| REGN1193; Anti-GCGR Reference Antibody | ||
| Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a KD of 0.1 nM. Crotedumab can be used for the research of diabetes. | ||
| M25390 | Dapiglutide | GLP Receptor |
| ZP7570 | ||
| Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. | ||
| M25470 | Mazdutide acetate | Glucagon Receptor |
| IBI362 acetate; LY3305677 acetate | ||
| Mazdutide (IBI362, LY3305677) is a novel glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist. It can be used in studies of obesity and type 2 diabetes (T2D). | ||
| M28035 | TT-OAD2 free base | GLP Receptor |
| TT-OAD2 free base is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM. TT-OAD2 free base has the potential for diabetes treatment. | ||
| M29583 | TT-OAD2 | GLP Receptor |
| TT-OAD2 is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM. TT-OAD2 has the potential for diabetes treatment. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
